View Project

1. To Identify Hair Follicle-Specific Androgen Receptor (AR) Epitopes for Targeted Vaccine Development.Use advanced bioinformatics and structural biology tools to pinpoint unique epitopes in the DHT-binding region of androgen receptors localized in hair follicles.

2. To Design and Formulate a Precision Vaccine to Block DHT-AR Interaction. Develop an innovative vaccine platform (peptide based) incorporating hair follicle-specific AR epitopes and optimized adjuvants to elicit a specific immune response.

3. To Evaluate the Vaccine’s Efficacy and Safety in Preclinical Models Conduct in vitro and in vivo studies (Androgenic alopecia C57BL/6 mice model) to assess the vaccine's ability to block DHT binding, promote hair regrowth, and ensure no systemic androgenic interference.

Androgenic alopecia, or male pattern baldness, affects millions worldwide and is driven by dihydrotestosterone (DHT) binding to androgen receptors (ARs) in hair follicles. This interaction leads to follicle miniaturization, hair loss, and reduced quality of life for affected individuals. Current treatments, such as 5-alpha reductase inhibitors, often result in short-term effectivness and systemic side effects, creating an urgent need for a safer and more targeted therapeutic approach.

This project, titled "ImmunoShield: Development of a Precision Vaccine Targeting DHT - Hair-Follicles Receptor Region for Androgenic Alopecia," aims to revolutionize hair loss treatment by developing a precision vaccine that selectively blocks DHT-AR interactions in hair follicles. Using advanced bioinformatics and structural biology, unique hair follicle-specific AR epitopes in the DHT-binding region will be identified for vaccine design.

The vaccine platform will leverage peptide-based technology combined with optimized adjuvants to elicit a localized immune response, targeting androgen receptors in hair follicle cells while preserving systemic androgenic functions. Preclinical studies will rigorously evaluate the vaccine’s efficacy in blocking DHT binding, promoting hair regrowth, and ensuring safety in both in vitro and in vivo models. Subsequently, early-stage clinical trials will be planned to assess immunogenicity, localized effects, and overall safety in men with androgenic alopecia.

By offering a long-term, minimally invasive solution with minimal side effects, ImmunoShield holds the potential to redefine the treatment landscape for androgenic alopecia, restoring confidence and quality of life for millions of individuals suffering from hair loss.

1. Identification of Target Epitopes:

Unique androgen receptor (AR) epitopes specific to hair follicles identified using bioinformatics and structural biology, forming the basis for vaccine design.

2. Vaccine Prototype Development:

A precision peptide-based vaccine incorporating hair follicle-specific AR epitopes and optimized adjuvants, with protocols for scalable production.

3. Preclinical Validation:

In vitro evidence of vaccine-induced antibodies blocking DHT-AR interactions. In vivo data demonstrating efficacy in promoting hair regrowth and safety, with no systemic androgenic interference in androgenic alopecia C57BL/6 mice model.

4. Knowledge Dissemination, Clinical trials and Scalability:

Publications, patents, and conference presentations to share findings. Documentation supporting scalable production and Phas 1 trials.

The ImmunoShield project is expected to have a significant impact by providing a long-term, minimally invasive solution for androgenic alopecia, improving the physical and psychological well-being of individuals affected by male pattern baldness. Developing a precision vaccine that selectively targets androgen receptors in hair follicles offers a safer alternative to current treatments like 5-alpha reductase inhibitors, which have systemic side effects. This approach enhances patient safety and advances precision medicine by introducing targeted treatments for receptor-specific conditions. Economically, it reduces the financial burden of ongoing hair loss treatments and provides a cost-effective, durable solution, potentially creating new opportunities in the biotech and dermatological sectors. Socially, the project aims to restore confidence and improve emotional well-being, helping individuals overcome the stigma associated with hair loss and fostering greater social engagement.

Additionally, the project contributes to scientific research by advancing knowledge in hair follicle biology and androgen receptor interactions, establishing a novel platform for developing targeted vaccines for other receptor-mediated conditions. The project aligns with SDG 3: Good Health and Well-being by providing accessible, effective healthcare solutions and contributes to SDG 9: Industry, Innovation, and Infrastructure by promoting innovation in the biopharmaceutical industry. Ultimately, ImmunoShield will deliver both direct and indirect benefits, transforming the treatment of androgenic alopecia and contributing to global health and scientific progress.